Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC002 vs Humira in active ankylosing spondylitis
CTR20201600Phase 3Completed
- Sponsor
- Shandong Danhong Pharmaceutical
- Start
- Aug 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of BC002 in ankylosing spondylitis (AS), sponsored by Shandong Danhong Pharmaceutical. Started Aug 2020; status: completed.
02
Drugs
BC002
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20201600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201600.